QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-downgrades-cidara-therapeutics-to-neutral

Guggenheim analyst Seamus Fernandez downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Neutral.

 hc-wainwright--co-downgrades-cidara-therapeutics-to-neutral

HC Wainwright & Co. analyst Sara Nik downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Neutral.

 needham-downgrades-cidara-therapeutics-to-hold

Needham analyst Joseph Stringer downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Hold.

 merck-makes-big-bet-on-flu-protection-with-cidara-buyout

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Core News & Articles

https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae

 why-is-cidara-therapeutics-cdtx-stock-trending-overnight

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

 rbc-capital-maintains-outperform-on-cidara-therapeutics-raises-price-target-to-145

RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:CDTX) with a Outperform and raises the price target...

 needham-maintains-buy-on-cidara-therapeutics-raises-price-target-to-135

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $100...

 update-cidara-therapeutics-q3-adj-eps-143-misses-135-estimate

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION